AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11493740
Drug: Medium-molecular-weight HES
RxNorm normalized name: chitosan medium molecular weight (200-800 MPA.S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-molecular-weight HES preparation (6% HES, MW 200,000/0.5)
Trial: 11493740
Drug: High-molecular-weight HES
RxNorm normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-molecular-weight HES preparation (6% HES, MW 450,000/0.7)
Trial: 9615959
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy focusing on respiration, loudness, articulation, prosody, and intonation
Trial: 9093728
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of oral 5-HT3 antagonists (ondansetron 8 mg b.i.d. or dolasetron 200 mg daily) plus dexamethasone 8 mg p.o. daily
Trial: 2202553
Drug: 2.5% percutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% percutaneous niflumic acid gel applied 3-times daily for 7 days
Trial: 2202553
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied 3-times daily for 7 days
Trial: 23770110
Drug: Self-management training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management training sessions with individualized action plans for COPD and comorbidities, linked to daily symptom diaries for 12 months.
Trial: 21917304
Drug: Tamsulosin oral
RxNorm normalized name: tamsulosin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin oral controlled absorption system 0.4 mg/d for 1 month
Trial: 21917304
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical care (corticosteroids and analgesics)
Trial: 8908377
Drug: DNA-recombinant insulin
RxNorm normalized name: Insulin Glulisine (recombinant DNA origin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA-recombinant insulin
Trial: 31915175
Drug: Early integration
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early integration of palliative care (EIPC) on a monthly basis
Trial: 28943117
Drug: 0.4 mL
RxNorm normalized name: ethanol 0.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mL of 14% benzocaine plus 0.2% benzocaine
Trial: 21555333
Drug: Alcohol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (mean breath alcohol concentration = 68 mg/dL)
Trial: 21555333
Drug: No-alcohol control
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No-alcohol control (0 mg/dL)
Trial: 17894701
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream (1%)
Trial: 27854116
Drug: 100% orange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% orange juice with vitamin C 70 mg daily (G2)
Trial: 31239304
Drug: Albuterol inhaled
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol inhaled with gas flow of 50 L/min
Trial: 31239304
Drug: Albuterol inhaled
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol inhaled with GF:IF=1.0
Trial: 31239304
Drug: Albuterol inhaled
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol inhaled with GF:IF=0.5
Trial: 31239304
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL saline inhaled before albuterol doses
Trial: 28285649
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) treatment for 12 weeks
Trial: 25956370
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) and hMG administered simultaneously
Trial: 21155616
Drug: Manidipine 10
RxNorm normalized name: manidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manidipine 10 mg/Lisinopril 10 mg
Trial: 10792142
Drug: 1.0 microgram.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 microgram.kg‐1 intravenous fentanyl
Trial: 9497468
Drug: Gas tamponade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gas tamponade with autologous platelet concentrate (16% C3F8 gas + 0.1 ml autologous platelet concentrate)
Trial: 7686981
Drug: Leuprolide (luteinizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide (luteinizing hormone-releasing hormone agonist) given as an injection every 28 days for 24 weeks
Trial: 7539852
Drug: Leuprolide (luteinizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide (luteinizing hormone-releasing hormone agonist)
Trial: 27814472
Drug: Selenium (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (200 μg once a day)
Trial: 17570513
Drug: Fludarabine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30 mg/m² for 6 days and oral busulfan 4 mg/kg/day for 2 days
Trial: 16088264
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (autogenic training +/− pill placebo)
Trial: 12187208
Drug: Monthly leuprolide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly leuprolide acetate (7.5 mg)
Trial: 12187208
Drug: 3-month leuprolide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-month leuprolide acetate (22.5 mg)
Trial: 10442361
Drug: Oxaliplatin and
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin and UFT/oral calcium folinate
Trial: 10442361
Drug: UFT/oral calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT/oral calcium folinate
Trial: 2132171
Drug: Ketanserin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (0.1 mg/min for 24 h)
Trial: 786666
Drug: Azathioprine (AZ)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZ) 1.5 ‐ 2.0 mg/kg/day
Trial: 16562817
Drug: Lean pork
RxNorm normalized name: Pork
DrugBank: Pork (DB10561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean pork (150 g per day)
Trial: 16562817
Drug: Veal (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veal (150 g per day)
Trial: 12679825
Drug: Milk fermented
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fermented with yoghurt cultures and L. casei DN‐114001 for 3 weeks
Trial: 10980510
Drug: multiparticulate capsule
RxNorm normalized name: Microparticulate beta-(1,3)(1,6) glucan from saccharomyces cerevisiae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiparticulate capsule (V)
Trial: 9315418
Drug: Allendale-N9 film
RxNorm normalized name: (.alpha.3,.alpha.6,.alpha.9-tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-.kappa.n3,.kappa.n6,.kappa.n9,.kappa.n15,.kappa.o3,.kappa.o6,.kappa.o9)gadolinium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allendale-N9 film containing 100 mg N-9
Trial: 9315418
Drug: Allendale-N9 film
RxNorm normalized name: (.alpha.3,.alpha.6,.alpha.9-tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-.kappa.n3,.kappa.n6,.kappa.n9,.kappa.n15,.kappa.o3,.kappa.o6,.kappa.o9)gadolinium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allendale-N9 film containing 130 mg N-9
Trial: 9315418
Drug: VCF containing
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCF containing 70 mg N-9
Trial: 26906148
Drug: Exercise Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise Training (ET) on a cycle ergometer, performed daily at 50%-60% of maximal exercise capacity for 12 months.
Trial: 22327039
Drug: Oral CR
RxNorm normalized name: Oral Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CR oxycodone 10 mg/q12h plus IV paracetamol 1g/q6h
Trial: 22327039
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia with continuous infusion of levobupivacaine 0.125% and sufentanil 0.7 mcg/mL at 7 mL/h
Trial: 20231783
Drug: CONV (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CONV (conventional treatment)
Trial: 18042917
Drug: GIK infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIK infusion therapy
Trial: 16518521
Drug: Propionylcarnitine (PLC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionylcarnitine (PLC) 600 mg as a single bolus followed by 1 mg/kg/min for 60 minutes
Trial: 2863674
Drug: Chloramphenicol alone
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloramphenicol alone by intramuscular injection
Trial: 2863674
Drug: Chloramphenicol plus
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloramphenicol plus penicillin by intravenous injection
Trial: 31504417
Drug: Canakinumab (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (50 mg)
Trial: 31504417
Drug: Canakinumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (150 mg)
Trial: 31504417
Drug: Canakinumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (300 mg)
Trial: 31504417
Drug: Canakinumab (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (any dose)
Trial: 31504417
Drug: IL-18 and
RxNorm normalized name: Bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-18 and IL-6 (baseline and on-treatment analyses)
Trial: 19066278
Drug: Single-drug taxane
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-drug taxane
Trial: 19066278
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anthracyclines with taxane
Trial: 19066278
Drug: Taxane-based combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane-based combination with capecitabine or gemcitabine
Trial: 19066278
Drug: Molecular targeted
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular targeted treatments
Trial: 12592331
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (HDMP) 900-600 mg/m(2) orally
Trial: 12592331
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose prednisolone 60 mg/m(2)/day orally
Trial: 12592331
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (HDMP) in high-risk subgroup
Trial: 12592331
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (HDMP) in high-risk subgroup aged </=2 or >/=10 years
Trial: 12592331
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (HDMP) in high-risk subgroup with WBC count >/=50 x 10(9)/l
Trial: 10229456
Drug: Group communication
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group communication treatment (5 hours weekly for 4 months)
Trial: 10229456
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment (support, performance, or movement groups)
Trial: 31556095
Drug: milrinone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: milrinone (0.4 and 0.8 µg/kg/min, n = 16)
Trial: 31556095
Drug: levosimendan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levosimendan (0.1 and 0.2 µg/kg/min, n = 15)
Trial: 30145660
Drug: Coronectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronectomy with adjunctive guided bone regeneration (GBR)
Trial: 24980988
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg QW plus topical agent as needed
Trial: 24980988
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Etanercept 50 mg BIW and Etanercept 50 mg QW plus topical agent)
Trial: 21871624
Drug: Atorvastatin 20mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg once daily
Trial: 15097153
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) 0.1 mg/kg daily (DD)
Trial: 15097153
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) 0.1 mg/kg alternate days (AD)
Trial: 10696916
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (IFNbeta-1a) treatment for 6 months
Trial: 9350882
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral vitamin A supplementation
Trial: 8223076
Drug: Lactogest (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactogest (4 capsules, approx 6000 IU)
Trial: 8223076
Drug: DairyEase (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DairyEase (2 tablets, approx 6000 IU)
Trial: 8223076
Drug: Lactogest (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactogest (2 capsules, approx 3000 IU)
Trial: 8223076
Drug: Enzyme treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme treatment (3000 or 6000 IU) with 50 g of lactose
Trial: 2433872
Drug: 0.25% methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% methotrexate cream
Trial: 30251591
Drug: High-dose ESS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ESS (1-hour daily during hospitalization)
Trial: 30251591
Drug: Low-dose ESS
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ESS (placebo)
Trial: 29064791
Drug: Quercetin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin at a dose of 120 mg per os daily added to standard treatment
Trial: 29064791
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without quercetin
Trial: 22093961
Drug: Small vessels
RxNorm normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small vessels treatment
Trial: 11601562
Drug: Supplement Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement Group (50 mg iron/day as amino acid chelate)
Trial: 9744373
Drug: Dorzolamide 2.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide 2.0% three times daily
Trial: 7527106
Drug: Trandolapril 4
RxNorm normalized name: trandolapril 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 4 mg o.d.
Trial: 6381166
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg b.i.d.
Trial: 7527106
Drug: Trandolapril +
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trandolapril + HCTZ 25 mg (if needed)
Trial: 7527106
Drug: Captopril +
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril + HCTZ 25 mg (if needed)
Trial: 2525984
Drug: Etodolac 200
RxNorm normalized name: etodolac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 200 mg three times a day
Trial: 2525984
Drug: Etodolac 300
RxNorm normalized name: etodolac 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 300 mg twice a day
Trial: 8458044
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg once a day
Trial: 2525984
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg three times a day
Trial: 31190151
Drug: Tissue-engineered substitute
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue-engineered substitute for autologous oral mucosa
Trial: 31190151
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of stem cells
Trial: 25803571
Drug: Weekly fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly fractionated IPL
Trial: 19439758
Drug: Local corticosteroid
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local corticosteroid injection (25 mg prednisolone)
Trial: 29072044
Drug: Radial shock
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial shock wave therapy
Trial: 17270320
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of Tdap and influenza vaccines
Trial: 17270320
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of influenza vaccine followed by Tdap
Trial: 31187169
Drug: Lapatinib 2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 2000 mg
Trial: 15826053
Drug: Phloem-fortified rye
RxNorm normalized name: Rye
DrugBank: Rye (DB10564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phloem-fortified rye bread (62 mg catechins, high polyphenol, HP)
Trial: 15826053
Drug: Phloem-fortified rye
RxNorm normalized name: Rye
DrugBank: Rye (DB10564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phloem-fortified rye bread (31 mg catechins, low polyphenol, LP)
Trial: 6125185
Drug: Atenolol 60
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 60 mg
Trial: 6125185
Drug: Fenoterol (inhaled)
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (inhaled)
Trial: 6125185
Drug: Histamine (inhaled)
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine (inhaled)
Trial: 26666236
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow cell therapy
Trial: 11804978
Drug: Intravenous fibrinolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fibrinolysis with alteplase
Trial: 11804978
Drug: Revascularization by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revascularization by stent placement with additional abciximab treatment
Trial: 7552860
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg orally, four times daily for 15 days)
Trial: 15374509
Drug: Cerebrolysin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin + multivitamin infusions
Trial: 15374509
Drug: Multivitamin infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin infusions alone
Trial: 6156059
Drug: IV gamma-globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV gamma-globulin (GG) 20 g IV given postoperatively
Trial: 30465722
Drug: Dexamethasone (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.15 mg/kg)
Trial: 14609970
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy plus gradual tapering of benzodiazepines (combined treatment)
Trial: 14609970
Drug: Gradual tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gradual tapering of benzodiazepines only (control group)
Trial: 8618283
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (2 cycles of 70 mg/m² cisplatin and 30 mg/m² doxorubicin with a 3-week interval)
Trial: 1414144
Drug: G‐DAMME (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐DAMME (0.25 mg iv)
Trial: 4022581
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (1% prednisolone acetate) in Group 2
Trial: 4022581
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group 1) with cycloplegic and topical antibiotic only
Trial: 24251579
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose control (addition of an oral glucose-lowering agent or commencement of insulin)